The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions
Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, summarizes the Phase I/II trial (NCT02912949) of zenocutuzumab in patients with solid tumors with NRG1 fusions. Zenocutuzumab is an anti-HER2/HER3 bispecific antibody targeting NRG1 fusion proteins and the trial included heavily pre-treated patients with pancreatic cancer, non-small cell lung cancer (NSCLC), and other solid tumors. Zenocutuzumab demonstrated promising results in all three cohorts with an acceptable safety profile and is a potential treatment for a subset of patients who have few therapeutic options. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
